Trial · NCT07913217
PNF Effects on Volleyball Performance
NCT07913217, Not applicable, Not yet recruiting, Uludag University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. PNF Effects on Volleyball Performance. Trials, record NCT07913217. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913217
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PNF Effects on Volleyball Performance
- NCT number
- NCT07913217
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Uludag University
- Conditions
- Sport Injuries
- Interventions
- Exercise
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Radar Gun | Six week | During the service, the speed of the athletes' spike shots will be measured. The athlete will be asked to assume a spiking position, while the evaluator will position themselves directly opposite the athlete. The athlete will be instructed to perform a spike at the highest possible speed. A total of three measurements will be taken, and the highest recorded speed will be used for analysis and evaluation. Athletes will not be provided with a rest period; instead, they will be asked to execute the spike as soon as they are ready (Kuyulu Haksal, 2024). |
| Primary | Scapular Dyskinesia Tests | 6 weeks | These tests evaluate scapular movement disorders. For static assessment, the Lateral Scapular Slide Test (LSST) is used; the distances of the medial and inferior angles of the scapula are measured in relation to the T3 and T7 vertebrae. A difference of more than 1.5 cm between the two sides is considered a positive result (Kibler, 2010). For dynamic assessment, the Kibler test is employed; scapular movement is observed while the athlete performs shoulder flexion/abduction movements while holding weights (Kibler, 2013). |
| Primary | Plank Test: | 6 weeks | This test evaluates the strength and stability of the core muscles. The athlete assumes a plank position with their elbows flexed at 90° and their body kept in a straight line. The timer is stopped when the athlete's form breaks. The test is |
| Primary | Seated Ball Throw Test: | 6 weeks | This test assesses the explosive power of the upper extremities. The athlete sits with their back against a wall and is instructed to throw a medicine ball forward from their chest with maximum force. The test is repeated three times, and the greatest distance achieved is used for analysis (Hermassi, 2010). |
| Primary | Upper Extremity Y-Balance Test: | 6 weeks | This test measures the dynamic stability of the upper extremities. With their hands on the floor, the athlete reaches in three directions (medial, inferolateral, and superolateral). Three trials are performed, and the furthest reach in each direction is recorded. Arm length (measured from the C7 vertebra to the tip of the middle finger) is recorded, and the results are normalized using the following formula: ((medial + inferolateral + superolateral) / (3 × arm length)) × 100 (Gorman, 2012; Westrick, 2012; Salo \& Chaconas, 2017). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers12
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913217
GET https://conductscience.org/api/trials/v1/NCT07913217/registered